LUMICKS
Amsterdam
About LUMICKS
LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $115.1M
- Funding stage: Late Stage Venture
- Last round: Debt Financing (Oct 2024)
- Website: lumicks.com
- Phone: 800-222-4545
Industries & Categories
Biotechnology, Life Science, Medical Device, Oncology
Social Profiles
Canonical: https://fsome.com/organization/lumicks-90465 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.